AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06160817 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative sharp debridement
Description: The debridement method for all patients, regardless of the assigned sequence, will involve the removal of non-viable tissue from the ulcer bed, edges, and perilesional skin using a scalpel (No. 3) with a No. 10 and/or No. 15 blade, along with Adson forceps and straight dissecting forceps.
Study NCT04940819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application for Dietary Management
Description: A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
Study NCT06189885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin with Daptomycin
Description: For patients randomized to receive daptomycin (8 mg/kg), the drug will be administered in a 50 cc bag, accompanied by a 500 cc bag of normal saline within 60 minutes before surgical incision and discontinued after 24 hours postoperatively.
Study NCT06189885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin with vancomycin
Description: Then vancomycin (15 mg/kg) will concurrently be given and completed within 60 minutes before surgical incision and discontinued after 24 hours postoperatively9. Patients in the vancomycin arm will receive this drug in a 50 cc bag accompanied by a 500 cc bag of normal saline.
Study NCT06401746 — intervention group
Intervention type: DEVICE
Intervention: Gastric Alimetry
Description: The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
Study NCT05931432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Well-Being Intervention
Description: The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions. The content of monthly text messaging resources and discussion topics for the peer-support groups will be informed by the Aim 1 qualitative findings.
Study NCT06349356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light with C.STIM device
Description: 4 flashes per treatment session
Study NCT06349356 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intense pulsed light with C.STIM device
Description: 4 flashes per treatment session
Study NCT05418751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Participants will received a manual therapy protocol consisting of the following techniques: manipulation of the occipito-atlanto-axial joint (C0-C1-C2), suboccipital inhibition technique, manipulation of the thoracolumbar hinge (T12-L1), global manipulation of the bilateral pelvis, global abdominal hemodynamic technique, functional technique of the pelvic diaphragm and stretching of the lumbopelvic musculature.
Study NCT05418751 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Participants will receive light contact on the same points and for the same amount of time as the experimental group, with no intention to treat.
Study NCT05150977 — intervention group
Intervention type: OTHER
Intervention: Polysomnography
Description: Reviewing collected data
Study NCT04875299 — intervention group
Intervention type: OTHER
Intervention: The study is observational
Description: The study is observational
Study NCT06433557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Description: For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
Study NCT05689775 — intervention group
Intervention type: PROCEDURE
Intervention: Reconstruction with robot-assisted rectus abdominis muscle flap
Description: Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.
Study NCT04809324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gross examination of the resection specimen
Description: measurement of the surgical margin by the operating surgeon using sterile scale, margins \<7mm will be revised on table
Study NCT04809324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frozen section
Description: frozen section evaluation of the specimen by the pathologist
Study NCT06250959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab Injection [Blincyto]
Description: Reduced-intensity chemotherapy followed by Blinatumomab
Study NCT06250959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: HyperCVAD regimen
Study NCT05490342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
Description: Blood test to value the antibody response to vaccination
Study NCT05029713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)
Description: The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off \<27 Kg in men and \<16 Kg in women and a standardized muscle mass cut-off \<0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.
Study NCT05050240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling Vest Procedure
Description: A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar_CoolFlow_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation.
Study NCT05050240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting overnight
Description: Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
Study NCT05133349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
Study NCT05487196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine belongs to the drug classification of antihypertensives
Study NCT05487196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine belongs to the drug classification of sedatives
Study NCT05487196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
Study NCT05487196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
Study NCT05487196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
Study NCT04682860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine N Butylbromide
Description: Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis
Study NCT04682860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of normal saline injection as placebo
Study NCT05387876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D intervention
Description: Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks
Study NCT05387876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
Study NCT06347328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echo-guided infiltration
Description: the subjects will receive their injection in the ultrasound room. a glucocorticoid injection is given at the time of consultation, using anatomical ultrasound scan to guide needle placement
Study NCT06347328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-echo-guided infiltration
Description: the subjects will receive their injection in the ultrasound room.~a glucocorticoid injection is given at the time of consultation, using anatomical landmarks to guide needle placement.~The investigator simulate an ultrasound scan with a film shown on the screen.
Study NCT06107998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stethoscope
Description: endotracheal tube cuff will be inflated via stethoscope guidance
Study NCT06107998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audible leak/Balloon palpation
Description: endotracheal tube cuff will be inflated via audible leak/balloon palpation method
Study NCT05852704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
Study NCT05852704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tab
Description: Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
Study NCT05541939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizagliflozin
Description: Encapsulated or Liquid Formulation
Study NCT04789382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LID018869+RepleniSH
Description: Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
Study NCT04789382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LID018869+Biotrue
Description: Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
Study NCT04789382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biofinity+RepleniSH
Description: Comfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
Study NCT04789382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PV+Biotrue
Description: Balafilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
Study NCT04705818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
Study NCT04705818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
Study NCT04727957 — intervention group
Intervention type: OTHER
Intervention: Diagnostic and prognostic models for VA-LRTIs
Description: Diagnostic and prognostic models for VA-LRTIs
Study NCT06338306 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus（FK506）
Description: Prograf
Study NCT05511857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-distancing, third-person self-talk.
Description: The participants will engage in self-distancing, third-person self-talk.
Study NCT05511857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-immersed, first-person self-talk.
Description: The participants will engage in self-immersed, first-person self-talk.
Study NCT05511857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: The participants will engage in a distraction task.
Study NCT05761353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endermologie
Description: Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.~Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.~-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care
Study NCT05761353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: Group B will receive negative pressure therapy with~* Pressure: 20-250 mmHg.~* Total treatment period: 6weeks~* A number of sessions: 3sessions/ week. Time of application : 30 min~* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care
Study NCT05700734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8510
Description: Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
Study NCT04955782 — intervention group
Intervention type: BEHAVIORAL
Intervention: samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
Description: The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer
Study NCT05842239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
Study NCT04846270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENA SmartCare Change Indicator
Description: Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
Study NCT04577638 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab and Intensity Modulated Radiotherapy (IMRT)
Description: Every included patient will receive the experimental treatment regimen as follows:~* Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks~* Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption.
Study NCT05257317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Medicine
Description: Where compression and traction movements will be carried out on these structures.~Technique called CV4, applied on the occipital, and Technique called asynchronous rolling of the temporal bones.
Study NCT05257317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapy
Description: Circular movements will be induced in a frontal and parietal bones
Study NCT06080516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell exercise
Description: Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
Study NCT04906629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
Study NCT04906629 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
Study NCT05859568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinna-located microphone
Description: Sound processors using a pinna-located microphone
Study NCT05859568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinna-simulated microphone algorithm
Description: Sound processors using a pinna-simulated algorithm
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent Meningococcal ABCYW vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Pharmaceutical form:Suspension-Route of administration:oral
Study NCT06647407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Pharmaceutical form:Suspension-Route of administration:oral
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTap-HepB-IPV-Hib vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTap-HepB-IPV-Hib vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTap-HepB-IPV-Hib vaccine
Description: Pharmaceutical form: Oral solution in tube Route of administration: oral
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTap-HepB-IPV-Hib vaccine
Description: Pharmaceutical form: Oral solution in tube Route of administration: oral
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06647407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT06378385 — intervention group
Intervention type: BEHAVIORAL
Intervention: Childhood Early Oral Aging Syndrome index
Description: Development and validation of a Childhood Early Oral Aging Syndrome index for the primary dentition as a diagnostic and epidemiological survey tool considering the current changes found in the pediatric population.
Study NCT05054803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ-MSC (XCEL-UMC-BETA)
Description: Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months